International Clinical Trial: Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129018) titled 'Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer' on Aug. 11.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Condition: Biliary Tract Cancer (BTC) First-line Therapy

Intervention: Drug: Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC

Recruitment Status: Not recruiting

Phase: Phase 2

Date ...